REGENXBIO Advances NAVSUNLI Toward Accelerated Approval
ROCKVILLE, Maryland, June 22, 2026 REGENXBIO has announced a significant regulatory milestone for NAVSUNLI⢠(clemidsogene lanparvovec-sngl, RGX-121), its investigational...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
ROCKVILLE, Maryland, June 22, 2026 REGENXBIO has announced a significant regulatory milestone for NAVSUNLI⢠(clemidsogene lanparvovec-sngl, RGX-121), its investigational...
NORTH CHICAGO, Illinois, and SAN FRANCISCO, California, June 22, 2026 AbbVie has announced a definitive agreement to acquire Apogee...
SYDNEY, Australia and AUCKLAND, New Zealand, June 21, 2026 MurjĀ®, a leading provider of cardiac device management software, has...
